Agreement - September 9, 2014
NeuroVive signs major agreement
The Swedish mitochondrial medicine company has signed an exclusive agreement worth USD 150 million with OnCore BioPharma. The agreement regards outlicensing of NVP018 for the treatment of chronic Hepatitis B virus infection. NeuroVive states that deal can give the company in total USD150 million in conditional milestone payments plus royalties on future drug sales. “After extensive discussions with a […]
Uncategorized - September 9, 2014
Aarhus University gets new research facilities
Advanced biomedical research facilities for EUR 114 million will soon begin to take shape in the University Park at Aarhus University. The first sod is being cut for a new building complex that will provide the future framework for the outstanding research at the Department of Biomedicine at Aarhus University. Comprising two parallel buildings containing new […]
Regulatory compliance - September 9, 2014
Novo Nordisk could get major fine
The company could get a fine of several millions for crimes against Russia’s competition law, reports Life Science Sweden. Russian competition authorities have found that Novo Nordisk could have breached the country’s competition law. The reason is reported to be a number of clauses in the company’s contract that limits competition. The purpose with the clauses […]
Drug development - September 8, 2014
BerGenBio granted platform patent
The Norwegian oncology biopharmaceutical company has announced that the United States Patent and Trademark Office (USPTO) has issued United States Patent 8,735,064 covering a method for creating and identifying functional interference RNA (RNAi) molecules. RNAis are recombinant nucleic acid molecules that have the ability to specifically down-regulate an expressed target gene in vivo. This patent protects BerGenBio’s CellSelect(TM) platform technology […]
Clinical Trials - September 8, 2014
Bavarian Nordic accelerates Ebola vaccine development
Bavarian Nordic A/S will accelerate its collaboration with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), on the development of its Ebola vaccine programs. Bavarian Nordic and partners are planning to initiate the first trial of a promising combination vaccine regimen in humans in 2015. Bavarian […]
In a new job - September 8, 2014
Kemwell gets new CEO
The contract pharmaceutical development and manufacturing company has appointed Mikael Ericson as new CEO. According to a statement from Kemwell Mikael Ericson is highly experienced in production, logistics and lean management and has held various international management positions in large corporations in both pharmaceutical and automotive industries, such as AstraZeneca, Scania and Plastal Industri. “With his […]
